Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health. New drugs for obesity ...

Recent study on dietary modifications and supplement use for endometriosis pain aimed to investigate the effectiveness of ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.

(Paris, France, Wednesday, 2 July 2025) A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated infertility are significantly more likely ...